Who owns Oruka Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of ORKA from SEC Form 13F filings across 256 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 256 institutions disclosed 74.1M shares of Oruka Therapeutics, Inc. worth $7.05B — about 117.9% of shares outstanding; the largest disclosed holder is FMR LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
256
13F holders
$7.05B
value, 2026 filers
117.9%
of shares outstanding (74.1M sh)
101
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of ORKA's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | 9.1M | $862.0M | 0.0% | 14.4% | +21.9% |
| 2 | BlackRock, Inc. | 5.0M | $474.9M | 0.0% | 7.9% | +41.5% |
| 3 | Venrock Adviser, LLC | 4.1M | $394.8M | 12.0% | 6.6% | 0.0% |
| 4 | Fairmount Funds Management LLC | 3.7M | $352.6M | 23.3% | 5.9% | 0.0% |
| 5 | Capital World InvestorsNEW | 3.4M | $323.7M | 0.0% | 5.4% | new |
| 6 | RTW INVESTMENTS, LP | 3.1M | $298.7M | 2.6% | 5% | +52.5% |
| 7 | STATE STREET CORP | 2.7M | $254.4M | 0.0% | 4.3% | +65.7% |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | 2.4M | $224.7M | 0.0% | 3.8% | +27.0% |
| 9 | Paradigm Biocapital Advisors LP | 2.1M | $204.1M | 3.8% | 3.4% | -7.6% |
| 10 | Deep Track Capital, LP | 1.9M | $183.3M | 2.7% | 3.1% | -5.3% |
| 11 | Bellevue Group AG | 1.7M | $157.7M | 3.3% | 2.6% | +226.9% |
| 12 | FRANKLIN RESOURCES INC | 1.6M | $154.3M | 0.0% | 2.6% | +61.5% |
| 13 | Remedium Capital Partners, LLC | 1.6M | $149.0M | 33.0% | 2.5% | 0.0% |
| 14 | RA CAPITAL MANAGEMENT, L.P.NEW | 1.6M | $148.0M | 1.3% | 2.5% | new |
| 15 | VIKING GLOBAL INVESTORS LP | 1.5M | $143.1M | 0.4% | 2.4% | -43.6% |
| 16 | GEODE CAPITAL MANAGEMENT, LLC | 1.4M | $136.1M | 0.0% | 2.3% | +49.8% |
| 17 | Jupiter Topco LLCNEW | 1.4M | $131.0M | 0.1% | 2.2% | new |
| 18 | PERCEPTIVE ADVISORS LLC | 1.3M | $128.0M | 1.9% | 2.1% | -3.6% |
| 19 | Polar Capital Holdings Plc | 1.2M | $116.9M | 0.3% | 2% | +17.3% |
| 20 | CITADEL ADVISORS LLC | 1.1M | $106.5M | 0.0% | 1.8% | +11.1% |
| 21 | T. Rowe Price Investment Management, Inc.NEW | 1.1M | $105.0M | 0.1% | 1.8% | new |
| 22 | BNP PARIBAS FINANCIAL MARKETS | 1.1M | $102.7M | 0.0% | 1.7% | +9773.9% |
| 23 | PRICE T ROWE ASSOCIATES INC /MD/ | 838,603 | $79.8M | 0.0% | 1.3% | +15.3% |
| 24 | Avidity Partners Management LP | 760,424 | $72.4M | 11.6% | 1.2% | 0.0% |
| 25 | SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLCNEW | 658,301 | $62.7M | 1.1% | 1% | new |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.